SEGMENT INFORMATION (Tables)

3 Months Ended

Jan. 31, 2022

Segment Reporting [Abstract]

Segment Profitability and Segment Assets

The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below:

	Three Months Ended
	January 31,
	2022		2021
	(in millions)
Net Revenue:
Life Sciences and Applied Markets	$	976	$	923
Diagnostics and Genomics	339		294
Agilent CrossLab	359		331
Total net revenue	$	1,674	$	1,548
Segment Income From Operations:
Life Sciences and Applied Markets	$	282	$	265
Diagnostics and Genomics	68		55
Agilent CrossLab	91		76
Total segment income from operations	$	441	$	396

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, short-term and long-term investments, deferred tax assets, right-of-use assets and other assets.  

	January 31, 2022		October 31, 2021
	(in millions)
Segment Assets:
Life Sciences and Applied Markets	$	3,752	$	3,741
Diagnostics and Genomics	3,325		3,320
Agilent CrossLab	870		839
Total segment assets	$	7,947	$	7,900

Reconciliation of segment results to total enterprise results

The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes: 

	Three Months Ended
	January 31,
	2022		2021
	(in millions)
Total segment income from operations	$	441	$	396
Transformational initiatives	(4)		(11)
Amortization of intangible assets related to business combinations	(51)		(44)
Acquisition and integration costs	(7)		(9)
Change in fair value of contingent consideration	(3)		—
Other	—		(4)
Interest income	1		—
Interest expense	(21)		(19)
Other income (expense), net (1)	(37)		3
Income before taxes, as reported	$	319	$	312

(1) For the three months ended January 31, 2022 and 2021, other income (expense), net includes net (gains) losses on the fair value of equity securities.